Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Key points
  • Monash IVF has named a new Managing Director.
  • The company has had a difficult year, botching two IVF procedures.
  • The new boss will not start until May next year.

Fertility company Monash IVF Ltd (ASX: MVF) has appointed a new Managing Director as the company looks to recover from what has been a challenging year.

The new boss, Dr Victoria Atkinson, will not start in the role until 18 May next year, however.

Monash IVF shares are currently changing hands for 66.5 cents, down 0.7% on the day and not far off their 12-month lows of 53.7 cents.

Female scientist working in a laboratory.

Image source: Getty Images

Poor operational execution

The company ran into trouble earlier this year when it emerged that it had botched two embryo transplants, with one of those incidents resulting in a woman giving birth to a genetically unrelated baby.

The company's shares tumbled from levels above $1 per share in April, when news of one of the incidents, which occurred in Brisbane, was reported in the media.

The company said in a statement at the time it had been aware of the incident since February, when it instigated an investigation which found human error was to blame.

Monash IVF's then-managing director, Michaal Knaap, who had led the company since 2019, resigned in June, and the company also dropped out of the S&P/ASX 300 Index (ASX: XKO) at its September rebalance.

Chair Richard Davis, in the company's annual report released earlier this month, apologised for the incidents, and reassured shareholders that, while the company had halted dividend payments for FY25, it did aim to reinstate dividends "provided performance aligns with the FY26 underlying NPAT guidance we provided … on 22 August".

A new start

Monash said on Tuesday that Dr Atkinson was "a distinguished healthcare executive" with more than 30 years of experience spanning clinical, operational, and governance roles in the public, private, and not-for-profit sectors.

The company went on to say:

Victoria's current role is the chief medical officer at Healthscope, where she oversees clinical strategy, governance, risk, medical affairs and medico-legal portfolios across a network of 36 hospitals, 15 intensive care units and 11 mental health facilities nationwide.  

The company said Dr Atkinson was a cardiothoracic surgeon by training, and also had a Master's in Health Management.

Mr Davis welcomed the appointment.

The board has undertaken a thorough search process and the Board is impressed that Victoria brings a unique combination of clinical and financial experience to the role. We are looking forward to Victoria bringing that focus to our people, our doctors and our patients.

Monash IVF was valued at $261.1 million at the close of trade on Monday.

Macquarie recently published a price target for Monash IVF shares of $1.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »